Live Oak Acquisition Corp. V
Price Targets
Analyst Ratings
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 11, 2026 | Compass Point | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Next Q | $-0.54 | $-0.54 — $-0.54 | 1 | |
| Current FY | $-0.84 | $-0.84 — $-0.84 | 1 | |
| Next FY | $-0.03 | $-0.03 — $-0.03 | 96% YoY | 1 |
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
No SEC filing reports analyzed yet. Reports are generated when new filings are detected and processed by the LLM pipeline.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Analyst Price Targets
| Metric | Value |
|---|---|
| Current Price | $10.55 |
| Target Low | $13.50 |
| Target Mean | $13.50 |
| Target Median | $13.50 |
| Target High | $13.50 |
| # Analysts | 1 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-03-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q 2026-06-30 |
$-0.54 | $-0.54 | $-0.54 | — | — | — | $0.2B | — | 1 |
| Current FY 2026-12-31 |
$-0.84 | $-0.84 | $-0.84 | — | — | — | $0.7B | — | 1 |
| Next FY 2027-12-31 |
$-0.03 | $-0.03 | $-0.03 | 96.4% | — | — | $1.2B | 66.4% | 1 |
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 11, 2026 | Compass Point | INITIATE | — | Buy |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.